Oncology Episode Payment Model in Hawaii

Breast Cancer Clinical Trial

Official title:

Oncology Episode Payment Model in Hawaii

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03523546
• Other study ID #: 823981A
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 1, 2018
• Est. completion date: January 31, 2026

Study information

• Verified date: March 2024
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.

Description:

The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 7
• Est. completion date: January 31, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any oncologist who practices with Hawaii Oncology and is a participating provider.

Exclusion Criteria:

• Any provider who does not practice with Hawaii Oncology.

Related Conditions & MeSH terms

• Breast Cancer
• Colon Cancer
• Colonic Neoplasms
• Lung Cancer

Intervention

Other:
• Cancer Episode Payment Model (CEM)
Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.

Locations

Country	Name	City	State
United States	Hawaii Oncology	Honolulu	Hawaii

Sponsors (2)

Lead Sponsor	Collaborator
University of Pennsylvania	Hawaii Medical Service Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite quality score	Quality metrics included in the oncology model will be compared across the two arms.	1 year
Primary	Episode cost	Total spending of oncology patients in the episode will be compared across the two arms.	6 months
Primary	Utilization of acute and specialty care	Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms	6 months
Secondary	Quality of care at end of life	Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms	6 months
Secondary	Survival	All cause mortality will be compared across the two arms	one year